United States - English - NLM (National Library of Medicine)

truemed group llc - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) -

European Union - English - EMA (European Medicines Agency)

samsung bioepis nl b.v. - etanercept - arthritis, psoriatic; arthritis, rheumatoid; psoriasis - immunosuppressants - rheumatoid arthritisbenepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.juvenile idiopathic arthritistreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.etanercept has not been studied in children aged less than 2 years.psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.axial spondyloarthritisankylosing spondylitistreatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).plaque psoriasistreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-a light (puva).paediatric plaque psoriasistreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

European Union - English - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - etanercept - arthritis, rheumatoid; arthritis, juvenile rheumatoid; arthritis, psoriatic; spondylarthropathies; spondylitis, ankylosing; psoriasis - immunosuppressants - rheumatoid arthritisnepexto in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.nepexto can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. nepexto is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.nepexto, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.juvenile idiopathic arthritistreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.etanercept has not been studied in children aged less than 2 years.psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.axial spondyloarthritisankylosing spondylitis treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.non-radiographic axial spondyloarthritis treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).plaque psoriasistreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-a light (puva).paediatric plaque psoriasistreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - etanercept - etanercept....50 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - etanercept __ -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - etanercept __ -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - etanercept __ -

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - etanercept - spondylitis, ankylosing; arthritis, juvenile rheumatoid; arthritis, psoriatic; psoriasis; arthritis, rheumatoid - immunosuppressants - rheumatoid arthritis enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. juvenile idiopathic arthritis treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. enbrel has not been studied in children aged less than two years. psoriatic arthritis treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease. axial spondyloarthritis ankylosing spondylitis (as) treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. non-radiographic axial spondyloarthritis treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids). plaque psoriasis treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-a light (puva). paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - etanercept - arthritis, psoriatic; spondylitis, ankylosing; psoriasis - immunosuppressants - rheumatoid arthritis;juvenile idiopathic arthritispsoriatic arthritis;axial spondyloarthritis;plaque psoriasis;paediatric plaque psoriasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 25mg - powder for injection with diluent - 25 mg - active: etanercept 25mg excipient: mannitol nitrogen sucrose trometamol water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.